Browsing by Author "Lemos Garcia, J"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Acute Kidney Injury in the Context of Inflammatory Bowel Disease - A Clinical CasePublication . Cristóvão Marques, J; Barata, R; Lemos Garcia, J; Navarro, D; Góis, M; Sousa, H; Cotovio, P; Ribeiro, F; Nolasco, FExtraintestinal manifestations of inflammatory bowel disease are common and extendable to all organs. Kidney and lower genitourinary system occurs in 4-23% of cases. This may be dependent on inflammatory bowel disease activity, secondary to metabolic disorders, drugs or others. We present a case of a 68-year-old man with ulcerative colitis for 22 years admitted in our department for acute nephritic syndrome. Urinary microscopy suggested glomerular injury. A kidney biopsy was performed and was compatible with acute interstitial nephritis and IgA nephropathy. Toxicity of mesalazine and glomerulonephritis secondary to ulcerative colitis were assumed. The patient suspended mesalazine and started prednisolone with clinical improvement. Our purpose is to sensitize the importance of having a prompt and thorough evaluation of acute kidney injury in patients with inflammatory bowel disease. We briefly review the broad spectrum of kidney manifestations in this population, focusing on mesalazine-induced nephrotoxicity.
- Transmural Remission Improves Clinical Outcomes Up to 5 years in Crohn's DiseasePublication . Raimundo Fernandes, S; Serrazina, J; Ayala Botto, I; Leal, T; Guimarães, A; Lemos Garcia, J; Rosa, I; Prata, R; Carvalho, D; Neves, J; Campelo, P; Ventura, S; Silva, A; Coelho, M; Sequeira, C; Oliveira, AP; Portela, F; Ministro, P; Tavares de Sousa, H; Ramos, J; Claro, I; Gonçalves, R; Araújo Correia, L; Tato Marinho, R; Cortez Pinto, H; Magro, FIntroduction: Evidence supporting transmural remission (TR) as a long-term treatment target in Crohn's disease (CD) is still unavailable. Less stringent but more reachable targets such as isolated endoscopic (IER) or radiologic remission (IRR) may also be acceptable options in the long-term. Methods: Multicenter retrospective study including 404 CD patients evaluated by magnetic resonance enterography and colonoscopy. Five-year rates of hospitalization, surgery, use of steroids, and treatment escalation were compared between patients with TR, IER, IRR, and no remission (NR). Results: 20.8% of CD patients presented TR, 23.3% IER, 13.6% IRR and 42.3% NR. TR was associated with lower risk of hospitalization (odds-ratio [OR] 0.244 [0.111-0.538], p < 0.001), surgery (OR 0.132 [0.030-0.585], p = 0.008), steroid use (OR 0.283 [0.159-0.505], p < 0.001), and treatment escalation (OR 0.088 [0.044-0.176], p < 0.001) compared to no NR. IRR resulted in lower risk of hospitalization (OR 0.333 [0.143-0.777], p = 0.011) and treatment escalation (OR 0.260 [0.125-0.540], p < 0.001), while IER reduced the risk of steroid use (OR 0.442 [0.262-0.745], p = 0.002) and treatment escalation (OR 0.490 [0.259-0.925], p = 0.028) compared to NR. Conclusions: TR improved clinical outcomes over 5 years of follow-up in CD patients. Distinct but significant benefits were seen with IER and IRR. This suggests that both endoscopic and radiologic remission should be part of the treatment targets of CD.